Kymera Therapeutics (KYMR) Liabilities and Shareholders Equity (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Liabilities and Shareholders Equity data on file, last reported at $1.7 billion in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $1.7 billion, up 81.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.6 billion (up 50.24% YoY), and the FY2025 annual result was $1.7 billion, up 78.2% from the prior year.
• Liabilities and Shareholders Equity eased to $1.7 billion in Q1 2026 per KYMR's latest filing, from $1.7 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $1.7 billion in Q4 2025 and troughed at $523.4 million in Q2 2022.
• A 5-year average of $877.8 million and a median of $826.0 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity fell 13.48% in 2023, then surged 87.34% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $603.1 million in 2022, then decreased by 4.54% to $575.8 million in 2023, then soared by 69.87% to $978.0 million in 2024, then soared by 78.2% to $1.7 billion in 2025, then retreated by 4.23% to $1.7 billion in 2026.
• Business Quant data shows KYMR's Liabilities and Shareholders Equity at $1.7 billion in Q1 2026, $1.7 billion in Q4 2025, and $1.1 billion in Q3 2025.